Clinical Trials Logo

Chronic Respiratory Diseases clinical trials

View clinical trials related to Chronic Respiratory Diseases.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04802317 Completed - Clinical trials for Chronic Respiratory Diseases

Intestinal Microbiota in COPD and Asthma

MicrObAs
Start date: June 23, 2020
Phase:
Study type: Observational

The composition of the intestinal microbiota, the level of lipopolysaccharides, TMAO in the blood, and other parameters of patients with COPD (n=50), asthma (n=50) and the control (n=40) will be assessed as factors associated with exacerbations and respiratory symptoms in the prospective study (12 months).

NCT ID: NCT02898129 Completed - Clinical trials for Chronic Respiratory Diseases

Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City

Start date: September 2016
Phase: N/A
Study type: Interventional

The research question is "Are the different types of house in Ho Chi Minh city equally contributing to chronic respiratory diseases?". According to this question, a cross-sectional and explorative study was set up to explore the differences in the environmental characteristics and prevalence of chronic respiratory diseases among common housing types in Ho Chi Minh city. Preliminary work was performed in 100 houses (20 houses per type, included tube houses, rental houses, rural houses, slum and apartment) from November 2013 to June 2015. It included measures by environmental devices, questionnaires and indoor activities diaries. This study will aim to collect information about the prevalence of chronic respiratory diseases (CRDs) inside those house types to understand more about role of house types in developing CRDs. The objective is: 1. to evaluate the relationships between the type of house and lung function of inhabitants in each housing type. 2. to evaluate the effects of environmental risk factors in each house type on prevalence of CRDs

NCT ID: NCT02517983 Completed - Clinical trials for Chronic Respiratory Diseases

Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam

Start date: August 2015
Phase: N/A
Study type: Observational

World Health Organization (WHO) considers chronic respiratory disease (CRD) as one of its four priorities. These diseases include asthma and rhinitis, chronic obstructive pulmonary diseases (COPD), occupational lung diseases, sleep apnoea syndromes, pulmonary hypertension, bronchiectasis and interstitial lung diseases. They constitute a serious public health problem in all countries throughout the world, in particular in low and middle income countries and in deprived populations. Hundreds of millions of people of all ages, in all countries of the world, are affected by chronic respiratory diseases. More than 50% of them live in low and middle income countries. Over 90% of deaths and the complete inability, due to CRDs occur in countries with low or middle incomes. The main causes of CRD are: tobacco smoke, occupational factors, indoor air pollution and outdoor air pollution, allergens, sequelae of respiratory infections such as tuberculosis. More than 30% of the population of Ho Chi Minh City (HCMC) could develop a CRD. In fact, 15% of children and 7% of adults could become asthma and 6% of the population could become COPD due to smoking. Children exposed to fumes from biomass burning, early in their life, seem to have a higher risk to develop COPD. The high level of air pollution in HCMC could aggravate asthma / COPD. Populations combining the rural risk (exposure to smoke from biomass) and the urban risk (smoking, pollution) may develop COPD much earlier (before age 40). Among the 9 million people in HCMC, 50% of the population is rural origin. Within this population, parasites could play a protective role against the risk of allergic asthma and consequently, the better control of helminthiasis among urban population, may result in allergic diseases such as asthma and anaphylaxis. Finally, the sequelae of tuberculosis (incidence is 200/100000) could participate to the morbidity of COPD / CRD. Study granted by the ARES-CUD ("Comission universitaire au développement")